Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.

Med Oncol · 2017 · PMC5550521 · PMID 28795333

Europe PMC DOI

hedged sentences

0.1550

closest p · 3.1× alpha

0.1550

boldest claim

The sentences

did not reach statistical significancep = 0.155not close (p > 0.1)

Overall survival The difference in overall median OS for patients receiving second-line cabazitaxel versus patients receiving second-line AR-targeted therapy did not reach statistical significance (10.2 vs. 15.1 months; p = 0.155).

also in 111,027 other papers

showed a trendno p-value reported

Results from the multivariate Cox regression showed a trend for OS in favor of cabazitaxel, although the results did not reach statistical significance (adjusted hazard ratio for cabazitaxel vs.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.